Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
All articles
Showing 73–84 of 411 articles
- Explore study findings
What happened to the trial in HIV-associated visceral obesity?
CJC-1295 With DAC is a growth hormone–releasing hormone analogue with a protein-binding attachment called a drug affinity complex. A historical phase 2 trial asked whether CJC-1295 could affect visceral obesity in people with HIV.
CJC-1295 With DAC2 sources (2005, 2024)
- Check methods and identity
Why a growth hormone study might also measure cortisol
CJC-1295 (No DAC) / GHRP-2 pairs a label commonly used for Mod GRF (1–29), a modified relative of growth hormone–releasing hormone, with GHRP-2, a synthetic six-amino-acid peptide also called pralmorelin.
CJC-1295 (No DAC) / GHRP-22 sources (2024, 2026)
- Interpret the evidence
What a two-peptide comparison showed about adding hormone responses
An older human experiment used unmodified GHRH(1–29) and GHRP-2 in eight healthy men. Each participant completed separate challenges with each compound and a challenge with both, in randomized order.
CJC-1295 (No DAC) / GHRP-22 sources (1995, 2024)
- Understand the science
Following two signals inside cultured pituitary cells
CJC-1295 (No DAC) / GHRP-2 lists two peptides expected to enter the growth hormone system at different points. The no-DAC label commonly means modified GHRH(1–29). GHRP-2 is a synthetic peptide that stimulates the growth hormone secretagogue pathway.
CJC-1295 (No DAC) / GHRP-22 sources (1998, 2024)
- Interpret the evidence
How researchers separated pulse regularity from average hormone output
CJC-1295 (No DAC) / GHRP-2 groups a modified growth hormone–releasing hormone fragment with pralmorelin, a six-residue ghrelin-receptor agonist. One research question is how the broader hormone environment can change the pattern observed when two signals act together.
CJC-1295 (No DAC) / GHRP-22 sources (2002, 2024)
- Interpret the evidence
Why food intake is a separate endpoint from growth hormone
CJC-1295 (No DAC) / GHRP-2 describes a pairing of a modified growth hormone–releasing hormone analogue with GHRP-2, also known as pralmorelin. Could a short growth hormone experiment by itself explain what happens to eating behavior?
CJC-1295 (No DAC) / GHRP-22 sources (2005, 2024)
- Check methods and identity
What would establish the identity of both compounds in a mixture?
CJC-1295 (No DAC) / GHRP-2 combines a name commonly used for the modified 29-residue growth hormone–releasing factor with pralmorelin, a six-residue peptide. A chemical identification of this exact pairing would have to account for both chains.
CJC-1295 (No DAC) / GHRP-23 sources (2010–2025)
- Explore study findings
What a stroke-model experiment tells us about identifying a peptide's partner
CJC-1295 (No DAC) / GHRP-6 pairs the label commonly used for modified growth hormone–releasing factor (1–29) with GHRP-6, a synthetic six-residue agonist of the ghrelin receptor. Can a study pairing GHRP-6 with a different molecule answer questions about this one?
CJC-1295 (No DAC) / GHRP-62 sources (2024, 2026)
- Interpret the evidence
Distinguishing a GHRP-6 heart study from evidence about the blend
CJC-1295 (No DAC) / GHRP-6 combines a name commonly used for a four-substitution relative of growth hormone–releasing hormone with GHRP-6, a six-residue peptide known to activate the ghrelin receptor.
CJC-1295 (No DAC) / GHRP-62 sources (2024, 2026)
- Understand the science
How structural studies show two different receptor targets
CJC-1295 (No DAC) / GHRP-6 names a modified growth hormone–releasing hormone (GHRH) fragment and a separate synthetic peptide that activates the ghrelin receptor. Structural research helps clarify what it means to give those two signals different receptor targets.
CJC-1295 (No DAC) / GHRP-63 sources (2020–2024)
- Understand the science
What happened when researchers blocked the body's own releasing signal?
CJC-1295 (No DAC) / GHRP-6 names a modified 29-residue analogue of growth hormone–releasing hormone (GHRH) plus a six-residue peptide that stimulates the ghrelin receptor. Does the growth hormone response to GHRP-6 depend on the body's existing GHRH activity?
CJC-1295 (No DAC) / GHRP-62 sources (1998, 2024)
- Explore study findings
Why a two-peptide challenge gave different results across groups
CJC-1295 (No DAC) / GHRP-6 combines a label for modified growth hormone–releasing factor (1–29) with GHRP-6, a ghrelin-receptor agonist. What would it take to interpret a response across people with different baseline characteristics?
CJC-1295 (No DAC) / GHRP-62 sources (2005, 2024)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
